Work

Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study

Year: 2024

Type: erratum

Source: Annals of Hematology

DOI: 10.1007/s00277-024-06020-3

Authors: Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Robin Carson, Rui Liu, Man Zhao, Xi Chen, Canchan Cui, Jian Hou, Jianxiang Wang

Institutions: Shanghai Changzheng Hospital, Seoul National University Bundang Hospital, Shanghai Jiao Tong University, Renji Hospital, Samsung Medical Center, Sungkyunkwan University, First Hospital of Jilin University, Chinese Academy of Medical Sciences & Peking Union Medical College, Chonnam National University, Chonnam National University Hwasun Hospital, First Affiliated Hospital Zhejiang University, Zhejiang University, Tianjin Medical University Cancer Institute and Hospital, Hong Kong Sanatorium and Hospital, Janssen Research & Development (United States), Xian Janssen Pharmaceutical Ltd. (China)

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,590

OpenAlex ID: W4402725824

Cites:

Cited by:

Related to: 10